Stockscreener 앱 받기
4.25
0.24%
0.010
시간 외 거래:
4.25
전일 마감가:
$4.24
열려 있는:
$4.82
하루 거래량:
13.24M
Relative Volume:
2.14
시가총액:
$1.27B
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-8.1731
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
+0.24%
1개월 성능:
+9.25%
6개월 성능:
+37.10%
1년 성능:
+53.43%
1일 변동 폭
$3.93
$5.01
1주일 범위
$3.93
$5.01
52주 변동 폭
$1.8906
$5.82
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.25 | 1.23B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera Biologics Reports Q2 2025 Financial Results - TipRanks
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
Earnings Flash (ABCL) AbCellera Biologics Inc. Reports Q2 Revenue $17.1M - MarketScreener
Is AbCellera Biologics Inc. stock overvalued or undervaluedOutstanding yields - Jammu Links News
Is AbCellera Biologics Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
What are AbCellera Biologics Inc. company’s key revenue driversOver 200% growth - Jammu Links News
What is the risk reward ratio of investing in AbCellera Biologics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
Why is AbCellera Biologics Inc. stock attracting strong analyst attentionMarket-beating returns - Jammu Links News
What is the dividend policy of AbCellera Biologics Inc. stockConsistently superior profits - Jammu Links News
How volatile is AbCellera Biologics Inc. stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
How many analysts rate AbCellera Biologics Inc. as a “Buy”Achieve breakthrough financial results - Jammu Links News
How does AbCellera Biologics Inc. generate profit in a changing economySuperior profit margins - Jammu Links News
What drives AbCellera Biologics Inc. stock priceMarket-leading growth rates - Jammu Links News
Does AbCellera Biologics Inc. stock perform well during market downturnsAchieve explosive financial results today - Jammu Links News
Is AbCellera Biologics Inc. a good long term investmentInvest smarter with daily trading signals - Jammu Links News
What analysts say about AbCellera Biologics Inc. stockInvest confidently with professional market insights - Jammu Links News
When is AbCellera Biologics Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
Should I hold or sell AbCellera Biologics Inc. stock in 2025Capitalize on fast-moving trading opportunities - Jammu Links News
What are the latest earnings results for AbCellera Biologics Inc.Beginner Investor Alerts For Fast Growth - Jammu Links News
Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Institutional Ownership: Sensitivity to Trading Actions Amid Market Cap Decline - AInvest
Institutional owners may ignore AbCellera Biologics Inc.'s (NASDAQ:ABCL) recent US$125m market cap decline as longer-term profits stay in the green - Yahoo Finance
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Is it the right time to buy AbCellera Biologics Inc. stockAdvanced Screener Report With High Returns - Jammu Links News
What is AbCellera Biologics Inc. company’s growth strategyExpert Picks Guidance For 2025 - Jammu Links News
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight - GlobeNewswire Inc.
Will AbCellera Biologics Inc. rebound enough to break evenDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
Published on: 2025-07-29 06:49:21 - metal.it
Why AbCellera Biologics Inc. stock attracts strong analyst attentionWeekly Return Pick Forecast Reports Show Trend - metal.it
Why AbCellera Biologics Inc. stock is on top investor watchlistsEntry Plan for Oversold Reversal Stocks Released - beatles.ru
How strong is AbCellera Biologics Inc. company’s balance sheetChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):